AGC Biologics and Repair Biotechnologies Form Partnership to Advance Novel mRNA Therapy Targeting Atherosclerosis
Friday, November 21, 2025
AGC Biologics has announced a new partnership with Repair Biotechnologies to develop and manufacture an innovative mRNA therapy aimed at reducing atherosclerotic plaque, a major cause of heart attacks and strokes. Unstable plaque rupture remains the world’s leading cause of death, contributing to around 27% of global mortality.
The collaboration will support the creation of an mRNA treatment designed to stabilise and shrink plaque in major blood vessels. Repair Biotechnologies aims to address atherosclerotic cardiovascular disease by removing excess toxic free cholesterol within cells, potentially reversing conditions once considered irreversible.
AGC Biologics will apply its full mRNA manufacturing capabilities, managing the entire process from plasmid DNA development to the final lipid nanoparticle-encapsulated drug product. This approach offers a streamlined and less risky path from early development to clinical production.
The partnership highlights the growing use of mRNA technology beyond infectious diseases, expanding into chronic and age-related conditions. AGC Biologics’ Heidelberg facility, which previously supplied plasmid DNA for the Pfizer-BioNTech COVID-19 vaccine, will support the project using advanced single-use systems that ensure faster and more flexible manufacturing. The site follows GMP standards aligned with both the European Medicines Agency and the U.S. FDA.
This collaboration aims to accelerate progress toward a therapeutic option that could significantly improve cardiovascular health and support longer, healthier lives.
Source: agcbio.com
